[{"id":"5ca3f586-5d57-495c-9088-bac9d19c4782","acronym":"","url":"https://clinicaltrials.gov/study/NCT04826341","created_at":"2021-04-01T16:52:34.686Z","updated_at":"2025-02-25T13:40:26.267Z","phase":"Phase 1/2","brief_title":"A Phase I/II Study of Sacituzumab Govitecan Plus Berzosertib in Small Cell Lung Cancer, Extra-Pulmonary Small Cell Neuroendocrine Cancer and Homologous Recombination-Deficient Cancers Resistant to PARP Inhibitors","source_id_and_acronym":"NCT04826341","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" BRCA1 • BRCA2 • HRD • CDK12 • BRCA • CHEK2 • RAD51B • BRIP1 • RAD51C • RAD51D • CHEK1 • BARD1 • RAD54L • FANCL • PPP2R2A","pipe":" | ","alterations":" ATM mutation • PALB2 mutation • CDK12 mutation • CHEK2 mutation • BRIP1 mutation • RAD51C mutation • RAD51D mutation • RAD51B mutation • BARD1 mutation • CHEK1 mutation • RAD54L mutation","tags":["BRCA1 • BRCA2 • HRD • CDK12 • BRCA • CHEK2 • RAD51B • BRIP1 • RAD51C • RAD51D • CHEK1 • BARD1 • RAD54L • FANCL • PPP2R2A"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ATM mutation • PALB2 mutation • CDK12 mutation • CHEK2 mutation • BRIP1 mutation • RAD51C mutation • RAD51D mutation • RAD51B mutation • BARD1 mutation • CHEK1 mutation • RAD54L mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e berzosertib (M6620) • Trodelvy (sacituzumab govitecan-hziy)"],"overall_status":"Recruiting","enrollment":" Enrollment 120","initiation":"Initiation: 09/20/2021","start_date":" 09/20/2021","primary_txt":" Primary completion: 03/01/2026","primary_completion_date":" 03/01/2026","study_txt":" Completion: 03/01/2027","study_completion_date":" 03/01/2027","last_update_posted":"2025-02-21"},{"id":"907c18db-1f38-4071-a1e3-b3af86377f13","acronym":"","url":"https://clinicaltrials.gov/study/NCT05941520","created_at":"2023-07-12T16:10:13.477Z","updated_at":"2025-02-25T13:49:53.635Z","phase":"Phase 2","brief_title":"Acolbifene Versus Low Dose Tamoxifen for the Prevention of Breast Cancer in Premenopausal Women at High Risk for Development of Breast Cancer","source_id_and_acronym":"NCT05941520","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" TP53 • PTEN • ATM • NF1 • MSH6 • CDH1 • CHEK2 • BRIP1 • RAD51C • RAD51D • BARD1 • NBN • AGR2","pipe":" | ","alterations":" TP53 mutation • ATM mutation • CHEK2 mutation • BRIP1 mutation • RAD51C mutation • RAD51D mutation • BARD1 mutation","tags":["TP53 • PTEN • ATM • NF1 • MSH6 • CDH1 • CHEK2 • BRIP1 • RAD51C • RAD51D • BARD1 • NBN • AGR2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e TP53 mutation • ATM mutation • CHEK2 mutation • BRIP1 mutation • RAD51C mutation • RAD51D mutation • BARD1 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e tamoxifen • acolbifene"],"overall_status":"Recruiting","enrollment":" Enrollment 80","initiation":"Initiation: 08/23/2024","start_date":" 08/23/2024","primary_txt":" Primary completion: 08/23/2027","primary_completion_date":" 08/23/2027","study_txt":" Completion: 09/01/2028","study_completion_date":" 09/01/2028","last_update_posted":"2025-02-21"},{"id":"73183b76-400c-42da-8908-2c1fc21637ec","acronym":"OPTIMUM","url":"https://clinicaltrials.gov/study/NCT05222971","created_at":"2022-02-05T18:29:24.003Z","updated_at":"2025-02-25T17:37:35.916Z","phase":"Phase 2","brief_title":"Olaparib with or Without Durvalumab for DDR Gene Mutated Biliary Tract Cancer Following Platinum-based Chemotherapy","source_id_and_acronym":"NCT05222971 - OPTIMUM","lead_sponsor":"Asan Medical Center","biomarkers":" BRCA1 • BRCA2 • ATM • POLE • BAP1 • MLH1 • MSH6 • MSH2 • BRCA • CHEK2 • RAD51 • FANCA • BRIP1 • RAD51C • RAD50 • RAD51D • CHEK1 • BARD1 • NBN • XRCC2 • FANCD2 • GEN1","pipe":" | ","alterations":" ATM mutation • CHEK2 mutation • BRIP1 mutation • BARD1 mutation","tags":["BRCA1 • BRCA2 • ATM • POLE • BAP1 • MLH1 • MSH6 • MSH2 • BRCA • CHEK2 • RAD51 • FANCA • BRIP1 • RAD51C • RAD50 • RAD51D • CHEK1 • BARD1 • NBN • XRCC2 • FANCD2 • GEN1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ATM mutation • CHEK2 mutation • BRIP1 mutation • BARD1 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Lynparza (olaparib) • Imfinzi (durvalumab)"],"overall_status":"Recruiting","enrollment":" Enrollment 62","initiation":"Initiation: 04/01/2022","start_date":" 04/01/2022","primary_txt":" Primary completion: 12/30/2025","primary_completion_date":" 12/30/2025","study_txt":" Completion: 12/30/2026","study_completion_date":" 12/30/2026","last_update_posted":"2025-01-28"},{"id":"36a397ed-0e68-47a2-95c4-59ca2210321e","acronym":"","url":"https://clinicaltrials.gov/study/NCT03601923","created_at":"2021-01-18T17:42:32.758Z","updated_at":"2025-02-25T13:18:35.093Z","phase":"Phase 2","brief_title":"Niraparib in Patients With Pancreatic Cancer","source_id_and_acronym":"NCT03601923","lead_sponsor":"Dana-Farber Cancer Institute","biomarkers":" BRCA1 • BRCA2 • ATM • CHEK2","pipe":" | ","alterations":" ATM mutation • PALB2 mutation • CHEK2 mutation","tags":["BRCA1 • BRCA2 • ATM • CHEK2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ATM mutation • PALB2 mutation • CHEK2 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Zejula (niraparib)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 32","initiation":"Initiation: 08/22/2018","start_date":" 08/22/2018","primary_txt":" Primary completion: 09/30/2025","primary_completion_date":" 09/30/2025","study_txt":" Completion: 02/28/2026","study_completion_date":" 02/28/2026","last_update_posted":"2024-10-22"},{"id":"75a29f57-27bd-4671-83cb-33821417c3f6","acronym":"","url":"https://clinicaltrials.gov/study/NCT03047135","created_at":"2021-01-18T15:00:24.273Z","updated_at":"2025-02-25T14:57:49.956Z","phase":"Phase 2","brief_title":"Olaparib in Men With High-Risk Biochemically-Recurrent Prostate Cancer Following Radical Prostatectomy, With Integrated Biomarker Analysis","source_id_and_acronym":"NCT03047135","lead_sponsor":"Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins","biomarkers":" BRCA1 • BRCA2 • ATM • CDK12 • CHEK2 • RAD51B • BRIP1 • RAD51C • RAD51D • CHEK1 • BARD1 • FANCL • PPP2R2A","pipe":" | ","alterations":" BRCA1 mutation • ATM mutation • PALB2 mutation • CDK12 mutation • CHEK2 mutation • BRIP1 mutation • RAD51C mutation • RAD51D mutation • RAD51B mutation • BARD1 mutation • CHEK1 mutation • CHEK1 expression","tags":["BRCA1 • BRCA2 • ATM • CDK12 • CHEK2 • RAD51B • BRIP1 • RAD51C • RAD51D • CHEK1 • BARD1 • FANCL • PPP2R2A"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRCA1 mutation • ATM mutation • PALB2 mutation • CDK12 mutation • CHEK2 mutation • BRIP1 mutation • RAD51C mutation • RAD51D mutation • RAD51B mutation • BARD1 mutation • CHEK1 mutation • CHEK1 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Lynparza (olaparib)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 51","initiation":"Initiation: 03/01/2017","start_date":" 03/01/2017","primary_txt":" Primary completion: 05/24/2023","primary_completion_date":" 05/24/2023","study_txt":" Completion: 05/01/2025","study_completion_date":" 05/01/2025","last_update_posted":"2024-07-03"},{"id":"64f232bf-1136-4191-96e8-05f7092ed952","acronym":"COMPRENDO","url":"https://clinicaltrials.gov/study/NCT05033756","created_at":"2021-09-05T16:55:47.679Z","updated_at":"2025-02-25T16:16:39.031Z","phase":"Phase 2","brief_title":"Comprehensive Analysis of Predictors of the Treatment With Pembrolizumab and Olaparib in Patients With Unresectable or Metastatic HER2 Negative Breast Cancer and a Deleterious Germline Mutation or a Homologous Recombination Deficiency (COMPRENDO","source_id_and_acronym":"NCT05033756 - COMPRENDO","lead_sponsor":"Institut fuer Frauengesundheit","biomarkers":" HER-2 • PGR • BRCA1 • BRCA2 • ATM • HRD • CHEK2 • RAD51C • RAD51D • BARD1 • XRCC2 • FANCC • SLX4","pipe":" | ","alterations":" HER-2 amplification • HER-2 negative • HRD • ATM mutation • PALB2 mutation • CHEK2 mutation • PGR positive • RAD51C mutation • RAD51D mutation • BARD1 mutation","tags":["HER-2 • PGR • BRCA1 • BRCA2 • ATM • HRD • CHEK2 • RAD51C • RAD51D • BARD1 • XRCC2 • FANCC • SLX4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 amplification • HER-2 negative • HRD • ATM mutation • PALB2 mutation • CHEK2 mutation • PGR positive • RAD51C mutation • RAD51D mutation • BARD1 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • Lynparza (olaparib)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 11","initiation":"Initiation: 07/30/2022","start_date":" 07/30/2022","primary_txt":" Primary completion: 01/01/2025","primary_completion_date":" 01/01/2025","study_txt":" Completion: 02/01/2026","study_completion_date":" 02/01/2026","last_update_posted":"2024-05-07"},{"id":"04495210-d346-4ec0-a195-5cf3933896b6","acronym":"","url":"https://clinicaltrials.gov/study/NCT05038839","created_at":"2021-09-09T13:53:06.097Z","updated_at":"2024-07-02T16:35:09.419Z","phase":"Phase 1","brief_title":"Cabozantinib and Pamiparib for the Treatment of Advanced of Refractory Solid Tumors","source_id_and_acronym":"NCT05038839","lead_sponsor":"M.D. Anderson Cancer Center","biomarkers":" BRCA1 • BRCA2 • PTEN • ARID1A • CHEK2 • RAD50 • PARP1 • CHEK1 • EMSY","pipe":" | ","alterations":" BRCA2 mutation • BRCA1 mutation • ATM mutation • PALB2 mutation • CHEK2 mutation • RAD50 mutation • CHEK1 mutation • CHEK1 expression","tags":["BRCA1 • BRCA2 • PTEN • ARID1A • CHEK2 • RAD50 • PARP1 • CHEK1 • EMSY"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRCA2 mutation • BRCA1 mutation • ATM mutation • PALB2 mutation • CHEK2 mutation • RAD50 mutation • CHEK1 mutation • CHEK1 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Cabometyx (cabozantinib tablet) • Partruvix (pamiparib)"],"overall_status":"Recruiting","enrollment":" Enrollment 44","initiation":"Initiation: 02/09/2022","start_date":" 02/09/2022","primary_txt":" Primary completion: 06/03/2024","primary_completion_date":" 06/03/2024","study_txt":" Completion: 06/03/2024","study_completion_date":" 06/03/2024","last_update_posted":"2024-04-16"},{"id":"691969a6-dc3e-4580-99bb-0a9ff4f0cef1","acronym":"NIRADO","url":"https://clinicaltrials.gov/study/NCT04779151","created_at":"2021-03-03T13:57:08.218Z","updated_at":"2024-07-02T16:35:12.913Z","phase":"Phase 2","brief_title":"Basket Trial Exploring the Efficacy and Safety of the Combination of Niraparib and Dostarlimab","source_id_and_acronym":"NCT04779151 - NIRADO","lead_sponsor":"Gustave Roussy, Cancer Campus, Grand Paris","biomarkers":" HER-2 • BRCA1 • BRCA2 • IDH1 • IDH2 • ARID1A • PBRM1 • CDK12 • CHEK2 • RAD51 • FANCA • BRIP1 • RAD51C • RAD51D • ARID2 • BARD1 • NBN • RAD54L • DRD","pipe":" | ","alterations":" HER-2 positive • HER-2 amplification • DDR • PBRM1 mutation • CDK12 mutation • CHEK2 mutation • BRIP1 mutation • RAD51C mutation • FANCA mutation • RAD51D mutation • BARD1 mutation • NBN mutation • DRD","tags":["HER-2 • BRCA1 • BRCA2 • IDH1 • IDH2 • ARID1A • PBRM1 • CDK12 • CHEK2 • RAD51 • FANCA • BRIP1 • RAD51C • RAD51D • ARID2 • BARD1 • NBN • RAD54L • DRD"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 positive • HER-2 amplification • DDR • PBRM1 mutation • CDK12 mutation • CHEK2 mutation • BRIP1 mutation • RAD51C mutation • FANCA mutation • RAD51D mutation • BARD1 mutation • NBN mutation • DRD"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Zejula (niraparib) • Jemperli (dostarlimab-gxly)"],"overall_status":"Suspended","enrollment":" Enrollment 51","initiation":"Initiation: 04/07/2021","start_date":" 04/07/2021","primary_txt":" Primary completion: 12/01/2024","primary_completion_date":" 12/01/2024","study_txt":" Completion: 12/01/2027","study_completion_date":" 12/01/2027","last_update_posted":"2024-03-26"},{"id":"e9a0c2de-92c2-4b8a-8b7f-5e473ce5f549","acronym":"ARIANES","url":"https://clinicaltrials.gov/study/NCT04276376","created_at":"2023-01-23T18:00:08.144Z","updated_at":"2024-07-02T16:35:12.843Z","phase":"Phase 2","brief_title":"Efficacy and Safety of the Combination of Rucaparib (PARP Inhibitor) and Atezolizumab (Anti-PD-L1 Antibody) in Patients With DNA Repair-deficient or Platinum-sensitive Solid Tumors","source_id_and_acronym":"NCT04276376 - ARIANES","lead_sponsor":"Gustave Roussy, Cancer Campus, Grand Paris","biomarkers":" BRCA1 • BRCA2 • ATM • CDK12 • CHEK2 • RAD51 • FANCA • BRIP1 • RAD51C • IL2 • RAD51D • BARD1 • NBN • RAD54L • DRD","pipe":" | ","alterations":" DDR • CDK12 mutation • CHEK2 mutation • BRIP1 mutation • RAD51C mutation • FANCA mutation • RAD51D mutation • BARD1 mutation • NBN mutation • DRD","tags":["BRCA1 • BRCA2 • ATM • CDK12 • CHEK2 • RAD51 • FANCA • BRIP1 • RAD51C • IL2 • RAD51D • BARD1 • NBN • RAD54L • DRD"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e DDR • CDK12 mutation • CHEK2 mutation • BRIP1 mutation • RAD51C mutation • FANCA mutation • RAD51D mutation • BARD1 mutation • NBN mutation • DRD"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Tecentriq (atezolizumab) • Rubraca (rucaparib)"],"overall_status":"Suspended","enrollment":" Enrollment 130","initiation":"Initiation: 04/12/2019","start_date":" 04/12/2019","primary_txt":" Primary completion: 12/01/2024","primary_completion_date":" 12/01/2024","study_txt":" Completion: 04/01/2025","study_completion_date":" 04/01/2025","last_update_posted":"2024-03-26"},{"id":"ac71a659-88ba-460b-8829-91700d494013","acronym":"ORCHID","url":"https://clinicaltrials.gov/study/NCT03786796","created_at":"2021-01-18T18:43:55.909Z","updated_at":"2025-02-25T15:08:13.487Z","phase":"Phase 2","brief_title":"Study of Olaparib in Metastatic Renal Cell Carcinoma Patients With DNA Repair Gene Mutations","source_id_and_acronym":"NCT03786796 - ORCHID","lead_sponsor":"Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins","biomarkers":" BRCA1 • BRCA2 • BAP1 • CDK12 • CHEK2 • RAD51B • BRIP1 • RAD51C • RAD51D • CHEK1 • BARD1 • RAD54L • FANCL","pipe":" | ","alterations":" ATM mutation • PALB2 mutation • CDK12 mutation • CHEK2 mutation • BRIP1 mutation • RAD51C mutation • RAD51D mutation • RAD51B mutation • BARD1 mutation • CHEK1 mutation • RAD54L mutation","tags":["BRCA1 • BRCA2 • BAP1 • CDK12 • CHEK2 • RAD51B • BRIP1 • RAD51C • RAD51D • CHEK1 • BARD1 • RAD54L • FANCL"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ATM mutation • PALB2 mutation • CDK12 mutation • CHEK2 mutation • BRIP1 mutation • RAD51C mutation • RAD51D mutation • RAD51B mutation • BARD1 mutation • CHEK1 mutation • RAD54L mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Lynparza (olaparib)"],"overall_status":"Recruiting","enrollment":" Enrollment 20","initiation":"Initiation: 06/03/2019","start_date":" 06/03/2019","primary_txt":" Primary completion: 03/01/2025","primary_completion_date":" 03/01/2025","study_txt":" Completion: 03/01/2026","study_completion_date":" 03/01/2026","last_update_posted":"2024-03-05"},{"id":"7235b2f2-0818-493f-a41a-c34684bbba42","acronym":"TRIUMPH","url":"https://clinicaltrials.gov/study/NCT03413995","created_at":"2021-01-18T16:50:34.963Z","updated_at":"2024-07-02T16:35:19.977Z","phase":"Phase 2","brief_title":"Trial of Rucaparib in Patients With Metastatic Hormone-Sensitive Prostate Cancer Harboring Germline DNA Repair Gene Mutations","source_id_and_acronym":"NCT03413995 - TRIUMPH","lead_sponsor":"Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins","biomarkers":" BRCA1 • BRCA2 • ATM • CHEK2 • FANCA • RAD51C • RAD50 • RAD51D • NBN • FANCF • FANCL • FANCI • FANCM • FANCD2 • FANCE • FANCG • FANCB • FANCC","pipe":" | ","alterations":" CHEK2 mutation • RAD51C mutation • FANCA mutation • RAD51D mutation • RAD50 mutation • FANCF mutation • NBN mutation • FANCG mutation • FANCI mutation • FANCM mutation","tags":["BRCA1 • BRCA2 • ATM • CHEK2 • FANCA • RAD51C • RAD50 • RAD51D • NBN • FANCF • FANCL • FANCI • FANCM • FANCD2 • FANCE • FANCG • FANCB • FANCC"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CHEK2 mutation • RAD51C mutation • FANCA mutation • RAD51D mutation • RAD50 mutation • FANCF mutation • NBN mutation • FANCG mutation • FANCI mutation • FANCM mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Rubraca (rucaparib)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 30","initiation":"Initiation: 09/10/2018","start_date":" 09/10/2018","primary_txt":" Primary completion: 11/08/2023","primary_completion_date":" 11/08/2023","study_txt":" Completion: 09/01/2024","study_completion_date":" 09/01/2024","last_update_posted":"2024-02-09"},{"id":"731ab927-ac32-42ee-9011-baa1124b987d","acronym":"","url":"https://clinicaltrials.gov/study/NCT05229588","created_at":"2022-02-12T17:48:13.004Z","updated_at":"2024-07-02T16:35:21.201Z","phase":"Phase 2","brief_title":"Lurbinectedin in Patients With Advanced Gastrointestinal Malignancies With DNA Repair Mutations","source_id_and_acronym":"NCT05229588","lead_sponsor":"HonorHealth Research Institute","biomarkers":" BRCA1 • BRCA2 • PTEN • ARID1A • CHEK2 • RAD51 • BRIP1 • NBN • EMSY","pipe":" | ","alterations":" BRCA1 mutation • ATM mutation • PTEN mutation • PALB2 mutation • CHEK2 mutation • BRIP1 mutation • NBN mutation • RAD51 mutation","tags":["BRCA1 • BRCA2 • PTEN • ARID1A • CHEK2 • RAD51 • BRIP1 • NBN • EMSY"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRCA1 mutation • ATM mutation • PTEN mutation • PALB2 mutation • CHEK2 mutation • BRIP1 mutation • NBN mutation • RAD51 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Zepzelca (lurbinectedin)"],"overall_status":"Recruiting","enrollment":" Enrollment 19","initiation":"Initiation: 06/14/2022","start_date":" 06/14/2022","primary_txt":" Primary completion: 08/31/2025","primary_completion_date":" 08/31/2025","study_txt":" Completion: 08/31/2026","study_completion_date":" 08/31/2026","last_update_posted":"2024-02-02"},{"id":"4c92b32e-341b-4687-bdb2-e542cce6f6c5","acronym":"","url":"https://clinicaltrials.gov/study/NCT04821141","created_at":"2021-03-29T11:52:25.247Z","updated_at":"2024-07-02T16:35:22.098Z","phase":"Phase 2","brief_title":"Phase IIB Trial of Bazedoxifene Plus Conjugated Estrogens","source_id_and_acronym":"NCT04821141","lead_sponsor":"University of Kansas Medical Center","biomarkers":" BRCA1 • BRCA2 • PTEN • STK11 • NF1 • CDH1 • CHEK2 • NBN","pipe":" | ","alterations":" PTEN mutation • PALB2 mutation • CHEK2 mutation • NBN mutation","tags":["BRCA1 • BRCA2 • PTEN • STK11 • NF1 • CDH1 • CHEK2 • NBN"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PTEN mutation • PALB2 mutation • CHEK2 mutation • NBN mutation"],"overall_status":"Recruiting","enrollment":" Enrollment 120","initiation":"Initiation: 12/14/2021","start_date":" 12/14/2021","primary_txt":" Primary completion: 07/31/2026","primary_completion_date":" 07/31/2026","study_txt":" Completion: 07/31/2027","study_completion_date":" 07/31/2027","last_update_posted":"2024-01-26"},{"id":"be84ddd3-f2ce-46d3-ae9d-39c0fd0d285e","acronym":"DIDO","url":"https://clinicaltrials.gov/study/NCT04983745","created_at":"2021-07-30T17:55:02.511Z","updated_at":"2024-07-02T16:35:25.580Z","phase":"Phase 2","brief_title":"Niraparib and Dostarlimab in HRD Solid Tumors","source_id_and_acronym":"NCT04983745 - DIDO","lead_sponsor":"West Cancer Center","biomarkers":" BRCA1 • BRCA2 • HRD • CDK12 • CHEK2 • RAD51B • BRIP1 • RAD51C • RAD51D • CHEK1 • BARD1 • RAD54L • FANCL • PPP2R2A • FANCI","pipe":" | ","alterations":" BRCA1 mutation • HRD • ATM mutation • PALB2 mutation • CHEK2 mutation • BRIP1 mutation • HRD + BRCA1 mutation • RAD51C mutation • RAD51D mutation • RAD51B mutation • BARD1 mutation • RAD54L mutation • FANCI mutation • RAD51 mutation","tags":["BRCA1 • BRCA2 • HRD • CDK12 • CHEK2 • RAD51B • BRIP1 • RAD51C • RAD51D • CHEK1 • BARD1 • RAD54L • FANCL • PPP2R2A • FANCI"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRCA1 mutation • HRD • ATM mutation • PALB2 mutation • CHEK2 mutation • BRIP1 mutation • HRD + BRCA1 mutation • RAD51C mutation • RAD51D mutation • RAD51B mutation • BARD1 mutation • RAD54L mutation • FANCI mutation • RAD51 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Zejula (niraparib) • Jemperli (dostarlimab-gxly)"],"overall_status":"Recruiting","enrollment":" Enrollment 30","initiation":"Initiation: 11/29/2021","start_date":" 11/29/2021","primary_txt":" Primary completion: 08/01/2024","primary_completion_date":" 08/01/2024","study_txt":" Completion: 08/01/2025","study_completion_date":" 08/01/2025","last_update_posted":"2023-12-21"},{"id":"a179cee7-5ed4-48d5-8b29-279b434cdab8","acronym":"PROGRESS","url":"https://clinicaltrials.gov/study/NCT05129605","created_at":"2021-11-22T14:53:36.295Z","updated_at":"2024-07-02T16:35:26.710Z","phase":"","brief_title":"Prostate Cancer Genetic Risk Evaluation and Screening Study","source_id_and_acronym":"NCT05129605 - PROGRESS","lead_sponsor":"Massachusetts General Hospital","biomarkers":" TP53 • BRCA1 • BRCA2 • MLH1 • MSH6 • MSH2 • CHEK2 • FANCA • BRIP1 • RAD51C • RAD51D • EPCAM • NBN • GEN1 • HOXB13","pipe":" | ","alterations":" CHEK2 mutation • BRIP1 mutation • RAD51C mutation • FANCA mutation • RAD51D mutation • PMS2 mutation • NBN mutation","tags":["TP53 • BRCA1 • BRCA2 • MLH1 • MSH6 • MSH2 • CHEK2 • FANCA • BRIP1 • RAD51C • RAD51D • EPCAM • NBN • GEN1 • HOXB13"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CHEK2 mutation • BRIP1 mutation • RAD51C mutation • FANCA mutation • RAD51D mutation • PMS2 mutation • NBN mutation"],"overall_status":"Recruiting","enrollment":" Enrollment 200","initiation":"Initiation: 02/12/2020","start_date":" 02/12/2020","primary_txt":" Primary completion: 12/01/2030","primary_completion_date":" 12/01/2030","study_txt":" Completion: 12/01/2040","study_completion_date":" 12/01/2040","last_update_posted":"2023-12-08"},{"id":"ff7c1831-8767-420c-a63e-fc4a8e3a8271","acronym":"","url":"https://clinicaltrials.gov/study/NCT04042831","created_at":"2021-01-18T19:49:54.652Z","updated_at":"2024-07-02T16:35:33.579Z","phase":"Phase 2","brief_title":"Olaparib in Treating Patients With Metastatic Biliary Tract Cancer With Aberrant DNA Repair Gene Mutations","source_id_and_acronym":"NCT04042831","lead_sponsor":"Academic and Community Cancer Research United","biomarkers":" BRCA1 • BRCA2 • PTEN • ARID1A • BRCA • CHEK2 • RAD51 • ATR • BRIP1 • NBN • EMSY","pipe":" | ","alterations":" BRCA2 mutation • BRCA1 mutation • ATM mutation • PTEN mutation • ARID1A mutation • PALB2 mutation • CHEK2 mutation • BRIP1 mutation • BRCA mutation • NBN mutation • EMSY mutation • RAD51 mutation","tags":["BRCA1 • BRCA2 • PTEN • ARID1A • BRCA • CHEK2 • RAD51 • ATR • BRIP1 • NBN • EMSY"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRCA2 mutation • BRCA1 mutation • ATM mutation • PTEN mutation • ARID1A mutation • PALB2 mutation • CHEK2 mutation • BRIP1 mutation • BRCA mutation • NBN mutation • EMSY mutation • RAD51 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Lynparza (olaparib)"],"overall_status":"Recruiting","enrollment":" Enrollment 36","initiation":"Initiation: 06/24/2020","start_date":" 06/24/2020","primary_txt":" Primary completion: 08/30/2024","primary_completion_date":" 08/30/2024","study_txt":" Completion: 03/30/2025","study_completion_date":" 03/30/2025","last_update_posted":"2023-10-13"},{"id":"6815fee1-32df-42b1-8b6f-aba0bb0f038b","acronym":"VA-BAT","url":"https://clinicaltrials.gov/study/NCT05011383","created_at":"2021-08-18T14:53:38.369Z","updated_at":"2024-07-02T16:35:39.749Z","phase":"Phase 2","brief_title":"High Dose Testosterone for ATM, CDK12 or CHEK2 Altered Prostate Cancers","source_id_and_acronym":"NCT05011383 - VA-BAT","lead_sponsor":"VA Office of Research and Development","biomarkers":" CDK12 • CHEK2","pipe":" | ","alterations":" ATM mutation • CDK12 mutation • CHEK2 mutation","tags":["CDK12 • CHEK2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ATM mutation • CDK12 mutation • CHEK2 mutation"],"overall_status":"Recruiting","enrollment":" Enrollment 51","initiation":"Initiation: 08/31/2021","start_date":" 08/31/2021","primary_txt":" Primary completion: 08/31/2026","primary_completion_date":" 08/31/2026","study_txt":" Completion: 08/31/2027","study_completion_date":" 08/31/2027","last_update_posted":"2023-08-17"},{"id":"12b373a9-f27e-4aa8-b2c5-2cb259826f62","acronym":"","url":"https://clinicaltrials.gov/study/NCT03718091","created_at":"2021-01-18T18:13:18.198Z","updated_at":"2024-07-02T16:35:43.598Z","phase":"Phase 2","brief_title":"M6620 (VX-970) in Selected Solid Tumors","source_id_and_acronym":"NCT03718091","lead_sponsor":"Massachusetts General Hospital","biomarkers":" BRCA1 • BRCA2 • MYC • ATM • ARID1A • CCNE1 • CDK12 • FBXW7 • ATRX • CHEK2 • FANCA • RAD51B • BRIP1 • RAD51C • RAD51D • BARD1 • NBN • FANCF • FANCM • FANCE • FANCC","pipe":" | ","alterations":" BRCA2 mutation • BRCA1 mutation • ATM mutation • ARID1A mutation • MYC amplification • CCNE1 amplification • CDK12 mutation • ATRX mutation • CHEK2 mutation • FBXW7 mutation • BRIP1 mutation • RAD51C mutation • FANCA mutation • RAD51D mutation • RAD51B mutation • BARD1 mutation • FANCF mutation • MRE11A mutation • NBN mutation • FANCM mutation","tags":["BRCA1 • BRCA2 • MYC • ATM • ARID1A • CCNE1 • CDK12 • FBXW7 • ATRX • CHEK2 • FANCA • RAD51B • BRIP1 • RAD51C • RAD51D • BARD1 • NBN • FANCF • FANCM • FANCE • FANCC"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRCA2 mutation • BRCA1 mutation • ATM mutation • ARID1A mutation • MYC amplification • CCNE1 amplification • CDK12 mutation • ATRX mutation • CHEK2 mutation • FBXW7 mutation • BRIP1 mutation • RAD51C mutation • FANCA mutation • RAD51D mutation • RAD51B mutation • BARD1 mutation • FANCF mutation • MRE11A mutation • NBN mutation • FANCM mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e berzosertib (M6620)"],"overall_status":"Completed","enrollment":" Enrollment 30","initiation":"Initiation: 01/08/2019","start_date":" 01/08/2019","primary_txt":" Primary completion: 06/01/2020","primary_completion_date":" 06/01/2020","study_txt":" Completion: 07/08/2020","study_completion_date":" 07/08/2020","last_update_posted":"2023-07-07"},{"id":"c66f765b-84b8-4be7-b6e5-f176047b0b9e","acronym":"","url":"https://clinicaltrials.gov/study/NCT04633902","created_at":"2021-01-19T20:37:04.111Z","updated_at":"2024-07-02T16:35:59.576Z","phase":"Phase 2","brief_title":"Phase II Study of Olaparib and Pembrolizumab in Advanced Melanoma With Homologous Recombination (HR) Mutation","source_id_and_acronym":"NCT04633902","lead_sponsor":"California Pacific Medical Center Research Institute","biomarkers":" BRAF • BRCA1 • BRCA2 • ARID1A • BAP1 • BRCA • CHEK2 • RAD51 • FANCA • BRIP1 • RAD50 • ARID2 • BARD1 • FANCD2 • RAD54B","pipe":" | ","alterations":" BRCA2 mutation • BRCA1 mutation • BRAF mutation • BRAF V600 • ATM mutation • ARID1A mutation • BAP1 mutation • CHEK2 mutation • BRIP1 mutation • FANCA mutation • RAD50 mutation • BARD1 mutation","tags":["BRAF • BRCA1 • BRCA2 • ARID1A • BAP1 • BRCA • CHEK2 • RAD51 • FANCA • BRIP1 • RAD50 • ARID2 • BARD1 • FANCD2 • RAD54B"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRCA2 mutation • BRCA1 mutation • BRAF mutation • BRAF V600 • ATM mutation • ARID1A mutation • BAP1 mutation • CHEK2 mutation • BRIP1 mutation • FANCA mutation • RAD50 mutation • BARD1 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • Lynparza (olaparib)"],"overall_status":"Recruiting","enrollment":" Enrollment 41","initiation":"Initiation: 03/03/2021","start_date":" 03/03/2021","primary_txt":" Primary completion: 06/30/2023","primary_completion_date":" 06/30/2023","study_txt":" Completion: 12/31/2024","study_completion_date":" 12/31/2024","last_update_posted":"2022-12-06"},{"id":"66ad1e5b-f099-4a22-b1d4-f866d0e6058a","acronym":"IMANOL","url":"https://clinicaltrials.gov/study/NCT03434158","created_at":"2021-01-18T16:56:23.710Z","updated_at":"2025-02-25T14:58:42.975Z","phase":"Phase 2","brief_title":"Olaparib Maintenance in Patients With MCRPC After Docetaxel Treatment Reaching Partial or Stable Response (IMANOL)","source_id_and_acronym":"NCT03434158 - IMANOL","lead_sponsor":"Spanish Oncology Genito-Urinary Group","biomarkers":" BRCA1 • BRCA2 • HRD • MLH1 • MSH6 • MSH2 • CHEK2 • RAD51C","pipe":" | ","alterations":" CHEK2 mutation","tags":["BRCA1 • BRCA2 • HRD • MLH1 • MSH6 • MSH2 • CHEK2 • RAD51C"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CHEK2 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Lynparza (olaparib) • docetaxel"],"overall_status":"Completed","enrollment":" Enrollment 16","initiation":"Initiation: 02/06/2018","start_date":" 02/06/2018","primary_txt":" Primary completion: 05/12/2022","primary_completion_date":" 05/12/2022","study_txt":" Completion: 05/12/2022","study_completion_date":" 05/12/2022","last_update_posted":"2022-11-03"},{"id":"194b16b8-2e75-4a35-9c4d-d18efa63c817","acronym":"PROact","url":"https://clinicaltrials.gov/study/NCT05167175","created_at":"2021-12-22T19:15:14.382Z","updated_at":"2025-02-25T15:00:10.570Z","phase":"Phase 2","brief_title":"The Study of Olaparib Combined With Abiraterone and Prednisone in mHSPC Patients With HRR Gene Mutation","source_id_and_acronym":"NCT05167175 - PROact","lead_sponsor":"Hongqian Guo","biomarkers":" BRCA1 • BRCA2 • HRD • CDK12 • CHEK2 • RAD51B • BRIP1 • RAD51C • RAD51D • CHEK1 • BARD1 • RAD54L • FANCL","pipe":" | ","alterations":" PALB2 mutation • CDK12 mutation • CHEK2 mutation • BRIP1 mutation • RAD51D mutation • RAD51B mutation • BARD1 mutation • RAD54L mutation","tags":["BRCA1 • BRCA2 • HRD • CDK12 • CHEK2 • RAD51B • BRIP1 • RAD51C • RAD51D • CHEK1 • BARD1 • RAD54L • FANCL"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PALB2 mutation • CDK12 mutation • CHEK2 mutation • BRIP1 mutation • RAD51D mutation • RAD51B mutation • BARD1 mutation • RAD54L mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Lynparza (olaparib) • abiraterone acetate • prednisone"],"overall_status":"Recruiting","enrollment":" Enrollment 30","initiation":"Initiation: 03/01/2022","start_date":" 03/01/2022","primary_txt":" Primary completion: 12/01/2024","primary_completion_date":" 12/01/2024","study_txt":" Completion: 12/01/2024","study_completion_date":" 12/01/2024","last_update_posted":"2022-10-25"},{"id":"a989b1b5-bcfc-450b-96cb-8e949d37b7ac","acronym":"ORZORA","url":"https://clinicaltrials.gov/study/NCT02476968","created_at":"2021-01-18T11:55:40.919Z","updated_at":"2024-07-02T16:36:04.179Z","phase":"Phase 4","brief_title":"To Assess the Efficacy and Safety of Olaparib Maintenance Monotherapy in the Treatment of Ovarian Cancer","source_id_and_acronym":"NCT02476968 - ORZORA","lead_sponsor":"AstraZeneca","biomarkers":" BRCA1 • BRCA2 • CDK12 • BRCA • MUC16 • CHEK2 • RAD51B • BRIP1 • RAD51C • CHEK1 • RAD54L • FANCL • PPP2R2A","pipe":" | ","alterations":" BRCA2 mutation • BRCA1 mutation • CHEK2 mutation • RAD51B mutation • BARD1 mutation • BRCA mutation","tags":["BRCA1 • BRCA2 • CDK12 • BRCA • MUC16 • CHEK2 • RAD51B • BRIP1 • RAD51C • CHEK1 • RAD54L • FANCL • PPP2R2A"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRCA2 mutation • BRCA1 mutation • CHEK2 mutation • RAD51B mutation • BARD1 mutation • BRCA mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Lynparza (olaparib)"],"overall_status":"Completed","enrollment":" Enrollment 181","initiation":"Initiation: 09/28/2015","start_date":" 09/28/2015","primary_txt":" Primary completion: 04/17/2020","primary_completion_date":" 04/17/2020","study_txt":" Completion: 12/17/2021","study_completion_date":" 12/17/2021","last_update_posted":"2022-09-10"},{"id":"88667f1b-98a0-4422-b87f-eee21f1cbfb9","acronym":"CHANGEABLE","url":"https://clinicaltrials.gov/study/NCT04508803","created_at":"2021-01-18T21:36:41.487Z","updated_at":"2024-07-02T16:36:08.019Z","phase":"Phase 2","brief_title":"Combination of HX008 And Niraparib in GErm-line-mutAted Metastatic Breast Cancer","source_id_and_acronym":"NCT04508803 - CHANGEABLE","lead_sponsor":"Fudan University","biomarkers":" HER-2 • BRCA1 • BRCA2 • PTEN • BAP1 • CDK12 • CHEK2 • FANCA • BRIP1 • RAD51C • RAD50 • RAD51D • CHEK1 • BARD1 • NBN • FANCF • WRN • FANCM • FANCD2 • FANCE • FANCC","pipe":" | ","alterations":" HER-2 positive • BRCA2 mutation • BRCA1 mutation • HR positive • HER-2 negative • ATM mutation • PALB2 mutation • CDK12 mutation • BAP1 mutation • CHEK2 mutation • BRIP1 mutation • RAD51C mutation • FANCA mutation • HR positive + HER-2 negative • RAD50 mutation • BARD1 mutation • BLM mutation • CHEK1 mutation • FANCF mutation • MRE11A mutation • NBN mutation • FANCM mutation • CHEK1 expression","tags":["HER-2 • BRCA1 • BRCA2 • PTEN • BAP1 • CDK12 • CHEK2 • FANCA • BRIP1 • RAD51C • RAD50 • RAD51D • CHEK1 • BARD1 • NBN • FANCF • WRN • FANCM • FANCD2 • FANCE • FANCC"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 positive • BRCA2 mutation • BRCA1 mutation • HR positive • HER-2 negative • ATM mutation • PALB2 mutation • CDK12 mutation • BAP1 mutation • CHEK2 mutation • BRIP1 mutation • RAD51C mutation • FANCA mutation • HR positive + HER-2 negative • RAD50 mutation • BARD1 mutation • BLM mutation • CHEK1 mutation • FANCF mutation • MRE11A mutation • NBN mutation • FANCM mutation • CHEK1 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Herceptin (trastuzumab) • cisplatin • Zejula (niraparib) • Puyouheng (pucotenlimab)"],"overall_status":"Recruiting","enrollment":" Enrollment 37","initiation":"Initiation: 09/14/2020","start_date":" 09/14/2020","primary_txt":" Primary completion: 11/20/2022","primary_completion_date":" 11/20/2022","study_txt":" Completion: 12/28/2022","study_completion_date":" 12/28/2022","last_update_posted":"2022-06-30"},{"id":"8ab88d0f-e9f2-4628-b4d7-1aff7c1af947","acronym":"PROspect","url":"https://clinicaltrials.gov/study/NCT05262608","created_at":"2022-03-02T16:52:32.144Z","updated_at":"2025-02-25T15:00:19.607Z","phase":"Phase 2","brief_title":"The Study of Olaparib in Newly Diagnosed mCRPC Patients With HRR Gene Mutation","source_id_and_acronym":"NCT05262608 - PROspect","lead_sponsor":"Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University","biomarkers":" BRCA1 • BRCA2 • HRD • CDK12 • CHEK2 • RAD51B • BRIP1 • RAD51C • RAD51D • CHEK1 • BARD1 • RAD54L • FANCL","pipe":" | ","alterations":" PALB2 mutation • CDK12 mutation • CHEK2 mutation • BRIP1 mutation • RAD51D mutation • RAD51B mutation • BARD1 mutation • RAD54L mutation","tags":["BRCA1 • BRCA2 • HRD • CDK12 • CHEK2 • RAD51B • BRIP1 • RAD51C • RAD51D • CHEK1 • BARD1 • RAD54L • FANCL"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PALB2 mutation • CDK12 mutation • CHEK2 mutation • BRIP1 mutation • RAD51D mutation • RAD51B mutation • BARD1 mutation • RAD54L mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Lynparza (olaparib)"],"overall_status":"Recruiting","enrollment":" Enrollment 30","initiation":"Initiation: 12/07/2021","start_date":" 12/07/2021","primary_txt":" Primary completion: 02/26/2024","primary_completion_date":" 02/26/2024","study_txt":" Completion: 04/26/2024","study_completion_date":" 04/26/2024","last_update_posted":"2022-03-02"}]